News

The resubmission was done following the issuing of complete response letter (CRL) by the FDA in February 2011. Taliglucerase alfa is Pfizer‘s proprietary plant cell expressed recombinant form

Crizotinib is indicated as a treatment for patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC). Bosutinib is indicated as a treatment for patients with newly

Australia’s Department of Health and Ageing is investing $466.7m over two years to build the PCEHR system which aids patients to control what is stored in health records,

The case was filed in connection with the submission of abbreviated new drug application (ANDA) for Frovatriptan Succinate EQ, 2.5mg base tablets with the US Food and Drug

The trial, which treated 12 patients in The Netherlands, evaluated RPL554 for a period of 6 days with daily doses in patients with mild asthma. The trial results

The company’s loss from operations for the second quarter of 2011 was $364,000, compared to $1.97m for the same period in 2010. For the six months ended 30

COTI-2 uses the company’s proprietary artificial intelligence system – Chemsas which uses a series of predictive computer models to identify compounds integrated in disease-specific drug discovery. COTI-2 inhibits

The deal covers Yemen, Syria, Tunisia, Sudan, Morocco, South Sudan, Jordan, Lebanon Libya, Algeria, Iraq and Egypt. Further details of the agreement were not disclosed. Hikma Pharma CEO

The study is intended to evaluate CUDC-101 when administered concurrently with radiation and cisplatin in human papillomavirus negative (HPV-) locally advanced head and neck cancer patients. The company